Figure 5–2 Overall study design of the safety run-in part



DLT = dose-limiting toxicity; RP3D = recommended phase III dose

Figure 5–3 Overall study design of Phase III part



FL = follicular lymphoma; FU = follow up; iNHL = indolent non-Hodgkin's lymphoma; PD= progressive disease; RP3D = recommended phase III dose

a:The maximum duration of treatment with copanlisib/placebo is 12 months (including combination therapy and monotherapy). Study treatment will be continued until occurrence of PD (per central independent blinded radiology review), clinical progression, unacceptable toxicity occurs, or until another criterion is met for withdrawal from study or up to 12 months whichever comes first.

b: Safety follow-up (FU) for patients who discontinue study treatment due to PD; Active FU for patients who complete 12 months' study treatment without PD or discontinue study treatment for any other reason than PD (includes Safety FU).